Last updated on October 2017

Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of QIVc in Subjects 2 to 18 Years of Age

Brief description of study

The randomized, observer-blind non-influenza comparator controlled study is intended to demonstrate the efficacy, immunogenicity, safety and tolerability of Seqirus' cell-based inactivated quadrivalent vaccine (QIVc) in subjects ≥2 years to <18 years of age

Clinical Study Identifier: NCT03165617

Contact Investigators or Research Sites near you

Start Over

Study Data Disclosure Manager

AusTrials Pty Ltd
Sherwood, Australia
  Connect »